Drugs / 61Cu-NODAGA-LM3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06455358 | Feb 2025 → Jun 2028 expected | neuroendocrine neoplasm | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 61Cu-NODAGA-LM3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455358 ↗ |
| Modality | Diagnostic / imaging agent | “shows promise as an imaging agent for SST2 expressing tumors.” NCT06455358 ↗ |
| Route | Intravenous | “Single intravenous administration of 61Cu-NODAGA-LM3” NCT06455358 ↗ |